Abstract
Radiation therapy (RT) is the standard of care approach for treatment of patients with primary uveal melanoma (UM). However, since the tumors are generally radioresistant, large fraction sizes of radiation are required to achieve tumor cell kill, which leads to an increase in normal tissue toxicity and frequently results in vision-threatening radiation complications. Activating somatic mutations in the G protein αq-subunit, GNAQ, have been recently identified to be present in approximately 50% of UM patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
